Healthcare

Under the 1-for-15 ratio, every fifteen existing shares will be consolidated into one new share, mechanically multiplying the per-share price by fifteen while dividing the share count by the same factor.

Severe uncontrolled asthma describes patients whose symptoms persist despite high-dose standard therapy, a population that continues to carry meaningful unmet need despite the arrival of several biologic therapies in the category over the past decade.

For clinical-stage biopharmaceutical companies operating between major data readouts, sustained analyst support of this kind often reflects continued confidence in the underlying science and pipeline breadth, rather than anticipation of a specific near-term catalyst. Monte Rosa (NASDAQ:GLUE) is known for its work in targeted …

This platform technology is integrated into the company's next-generation TRBC-based checkpoint inhibitors and T-cell engagers, HCW11-040 and HCW11-018b. TRBC-based constructs are engineered around T-cell receptorBetaconstant region targeting, an approach being explored as a way to direct T-cell engaging therapies with greater specificity. Both HCW11-040 …

Notably, the study reported no serious adverse events (SAEs) linked to paxalisib, a meaningful safety signal at this stage of development, particularly in a difficult-to-treat cancer population where tolerability can limit how aggressively a drug can be dosed.

The rating reiteration comes as Connect Biopharma (NASDAQ:CNTB) navigates a $36.7 million GAAP net loss, alongside second-quarter revenue of $2.94 million. A net loss of that scale against a comparatively small revenue base is typical for a clinical-stage biopharmaceutical company still investing heavily in …

Varsetatug masetecan is an antibody-drug conjugate (ADC) that targets EpCAM, a protein expressed on the surface of many solid tumor types, and delivers a Topo-1 payload — a cytotoxic agent — directly to cancer cells that express the target, a design intended to limit …